SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report
                (Date of earliest event reported): July 27, 2004

                           ARIAD PHARMACEUTICALS, INC.
             (Exact Name of Registrant as Specified in its Charter)


          Delaware                       0-21696                22-3106987
----------------------------      -----------------------  ------------------
(State or Other Jurisdiction     (Commission File Number)    (I.R.S. Employer
    of Incorporation)                                      Identification No.)


                              26 LANDSDOWNE STREET
                         CAMBRIDGE, MASSACHUSETTS 02139
              (Address of principal executive offices and zip code)


               Registrant's telephone number, including area code:
                                 (617) 494-0400








ITEM 5. OTHER EVENTS

On July 27, 2004, the Registrant disseminated a Press Release announcing that it
will provide a live webcast of its corporate  presentation at the Adams Harkness
24th Annual  Summer  Seminar on Tuesday,  August 3, 2004,  at the Marriott  Long
Wharf Hotel in Boston.  The presentation  will be given at 2 p.m. (ET) by Harvey
J. Berger, M.D., chairman and chief executive officer of ARIAD, who will provide
an overview of the Company and its progress in key programs.

The  information  contained  in the  Press  Release  dated  July  27,  2004,  is
incorporated herein by reference and attached as Exhibit 99.1 hereto.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.


           (c)    Exhibits.

                  99.1     The Registrant's Press Release dated July 27, 2004.



                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                             ARIAD PHARMACEUTICALS, INC.



                                             By:    /s/ Edward M. Fitzgerald
                                             ----------------------------------
                                                    Edward M. Fitzgerald
                                                    Senior Vice President and
                                                      Chief Financial Officer


Date:    July 27, 2004


                                        2


                                 EXHIBIT INDEX

Exhibit                                                            Sequential
Number     Description                                             Page Number
--------   -----------                                             -----------
99.1       The Registrant's Press Release dated July 27, 2004.         4


                                       3